axillary radiotherapy

RADIATION3 trials

Sponsors

Fudan University, University Hospitals of Derby and Burton NHS Foundation Trust, Hospital Universitari de Bellvitge

Conditions

Axillary Lymph Nodes DissectionBreast CancerChemotherapyNeoplasm, BreastRadiotherapy Side EffectSentinel Lymph Node

Unknown Phase

Axillary Radiotherapy for Early Stage Breast Cancer With Limited Positive Sentinel Lymph Nodes

Fudan UniversityBreast Cancer

Start: 2015-10-31Target: 475Updated: 2015-11-23

Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy

RecruitingNCT04109079

University Hospitals of Derby and Burton NHS Foundation TrustBreast Cancer, Neoplasm, Breast, Sentinel Lymph Node

Start: 2021-02-26End: 2030-02-28Target: 1900Updated: 2026-03-30

ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer

RecruitingNCT04889924

Hospital Universitari de BellvitgeAxillary Lymph Nodes Dissection, Breast Cancer, Chemotherapy +2

Start: 2021-06-11End: 2028-12-31Target: 820Updated: 2026-03-25

Related Papers

Omission of axillary lymph node dissection in patients with breast cancer with axillary pathological complete response confirmed by stained region lymph node biopsy after neoadjuvant systemic therapy (SrLNB study): study protocol for a single-arm, single-centre, phase-II trial

BMJ Open2025-03-01

Node marking techniques and targeted axillary dissection in patients with cN1 disease undergoing neoadjuvant chemotherapy: Analysis of initial 500 participants in the ATNEC trial.

Journal of Clinical Oncology2024-06-01

Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial)

Frontiers in Oncology2023-08-0920 citations

Practice patterns in ongoing neoadjuvant ATNEC trial for patients with cT1-3N1M0 breast cancer: Response to neoadjuvant chemotherapy (NACT), targeted axillary dissection and breast conservation rates.

Journal of Clinical Oncology2023-06-01

Abstract OT1-09-02: ATNEC: A multicentre, randomized trial investigating whether axillary treatment can be avoided in T1-3N1M0 breast cancer patients with no residual cancer in the axillary lymph nodes after neoadjuvant chemotherapy

Cancer Research2023-03-012 citations

ATNEC: A multicenter, randomized trial investigating whether axillary treatment can be avoided in patients with T1-3N1M0 breast cancer with no residual cancer in the lymph glands after neoadjuvant chemotherapy.

Journal of Clinical Oncology2022-06-019 citations

Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): multicentre randomised controlled trial and economic evaluation

BMJ2021-11-1068 citations

Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy (ATNEC).

Journal of Clinical Oncology2021-05-204 citations

Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study.

2021-03-29112 citations

Abstract OT-04-01: Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy - ATNEC (ClinicalTrials.gov NCT04109079)

Cancer Research2021-02-151 citations